A. Newlands

发表

Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults

R. Mehta, K. Hardes, D. Kelleher, 2011 .

Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD

R. Mehta, D. Kelleher, A. Preece, 2011 .

Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial

N. Zhong, C. Crim, Jinping Zheng, 2015, Current medical research and opinion.

Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects

R. Tal-Singer, R. Mehta, D. Kelleher, 2011 .

P152 The Impact of a Selective oral TRPV1 Antagonist in Patients with Chronic Cough

J. Smith, A. Woodcock, A. Kelsall, 2012, Thorax.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial.

J. Smith, A. Woodcock, A. Kelsall, 2014, The Journal of allergy and clinical immunology.

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

W. Fahy, D. Galkin, C. Kalberg, 2016, Drugs in R&D.

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

N. Zhong, Jinping Zheng, A. Church, 2015, International journal of chronic obstructive pulmonary disease.

Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist.

W. Fokkens, C. V. van Drunen, J. Denyer, 2014, British journal of clinical pharmacology.

TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis.

J. Bentley, J. Denyer, P. Bareille, 2014, International journal of clinical pharmacology and therapeutics.

Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial

C. Crim, D. Fairman, A. Newlands, 2023, PloS one.